|Rapid Review Complete
|Fondaparinux (Arixtra®) is indicated for the prevention of Venous Thromboembolic Events, treatment of Acute coronary syndrome, treatment of Superficial vein thrombosis, treatment of Deep vein thrombosis and acute Pulmonary Embolism.
|Rapid review commissioned
|Rapid review resubmission required
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that fondaparinux not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.